Compare MPV & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | IMUX |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 209.2M |
| IPO Year | N/A | 2013 |
| Metric | MPV | IMUX |
|---|---|---|
| Price | $16.32 | $16.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 24.3K | ★ 140.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.05 | $0.51 |
| 52 Week High | $21.00 | $16.86 |
| Indicator | MPV | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 66.47 |
| Support Level | $16.04 | $0.74 |
| Resistance Level | $17.57 | N/A |
| Average True Range (ATR) | 0.26 | 1.04 |
| MACD | 0.04 | 0.28 |
| Stochastic Oscillator | 69.33 | 90.27 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.